Results 1 to 10 of about 74,008 (160)

Janus Kinase inhibitors in the treatment of large vessel vasculitis: a systematic review and meta-analysis [PDF]

open access: yesOpen Medicine
This meta-analysis evaluates Janus Kinase (JAK) inhibitors’ efficacy and safety in large vessel vasculitis (LVV), encompassing Giant Cell Arteritis (GCA) and Takayasu’s Arteritis (TAK).
Bai Yang, Wang Zhe, Zhang Chunling
doaj   +2 more sources

Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions

open access: yesMolecules, 2023
Janus kinase inhibitors, also known as JAK inhibitors, JAKinibs or JAKi, are a new group of disease-modifying drugs. They work by inhibiting enzymes involved in the transmission of information from receptors located in the cell membrane to the cell ...
Izabella Ryguła   +2 more
doaj   +3 more sources

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives [PDF]

open access: yesPsoriasis: Targets and Therapy, 2019
Karen Ly,1 Kristen M Beck,1 Mary P Smith,1 Ana-Maria Orbai,2 Wilson Liao11Department of Dermatology, University of California San Francisco, San Francisco, CA, USA; 2Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USACorrespondence ...
Ly K   +4 more
doaj   +2 more sources

Janus kinase inhibitors - their current applications and future prospects [PDF]

open access: yesFarmacja Polska, 2022
Janus kinase inhibitors are a group of drugs that provide an alternative to conventional therapy for numerous diseases. The most studied drug of this group is tofacitinib.
Natalia Wierzbowska   +4 more
doaj   +1 more source

Itch and Janus Kinase Inhibitors

open access: yesActa Dermato-Venereologica, 2023
Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by 2 pathways, the histaminergic and non-histaminergic pathways.
Yujin Han   +4 more
doaj   +1 more source

Intraocular infections following biologicals and Janus Kinase inhibitors [PDF]

open access: yesIndian Journal of Ophthalmology
Parthopratim Dutta Majumder   +1 more
doaj   +2 more sources

Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment

open access: yesImmunological Medicine, 2023
Recent studies have gradually elucidated the pathogenesis of inflammatory bowel disease; thus, the Janus kinase (JAK)-signal transducers and activators of transcription pathway are strongly involved in the pathophysiology of inflammatory bowel disease ...
Hiroshi Nakase
doaj   +1 more source

In silico method potential therapeutic use of Janus Kinase inhibitors as severe acute respiratory syndrome coronavirus 2 main protease inhibitors

open access: yesJournal of the Scientific Society, 2023
Background: Coronavirus disease 2019 (COVID-19), it is an infectious respiratory disease caused by SARS corona virus 2 (SARS CoV-2). There are several reports of using JAK (Janus kinase)-inhibitors in persons with COVID-19 and the use of these decreased ...
Shankar Gharge   +3 more
doaj   +1 more source

Janus kinase inhibitors: between prescription authorization and reimbursability

open access: yesReumatismo, 2023
Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria ...
F.R. Spinelli   +5 more
doaj   +1 more source

JAK3 as an emerging target for topical treatment of inflammatory skin diseases [PDF]

open access: yes, 2016
The recent interest and elucidation of the JAK/STAT signaling pathway created new targets for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical formulations have shown beneficial results in psoriasis and alopecia ...
Alves de Medeiros, Ana   +5 more
core   +6 more sources

Home - About - Disclaimer - Privacy